Docket No. 2003-003R1 **PATENT**

1639

Unknown

Group Art Unit:

Examiner:

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

BY: Annie Wong

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Carlson et al.

Serial No.: 10/790,956

Filed: March 1, 2004

Evaluating Effects of Exposure For:

Conditions on Drug Samples Over Time

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Sir:

Transmitted herewith (check all that apply):

[] Preliminary Amendment	[X] Supplemental Information Disclosure Statement
[] Response/Amendment	[] Petition Under 37 CFR 1.97(d)(2)
[] Response/Amendment After Final	[] Formal Drawings
[] Supplemental Amendment	[] Declaration Under 37 CFR 1.131
[] Affidavits/Declarations	[] Declaration Under 37 CFR 1.132
[] Declaration and Power of Attorney	[] Terminal Disclaimer
[] Supplemental Declaration	[] Small Entity Statement
[] Associate Power of Attorney	[] Request for Refund
[] Change of Correspondence Address	[] Appeal
[] Associate Power of Attorney	[] Petition
[] Response to Missing Parts	[] Status Letter
to be filed in the above-identified patent app	lication.
INITIAL CONTRACTOR	
[X] No fee is required.	

[X] The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. § 1.16, in connection with the paper(s) transmitted herewith, or credit any overpayment of same, to Deposit Account No. 50-0496.

A duplicate copy of this Transmittal Letter is transmitted herewith.

Date: 10/79/04

Symyx Technologies, Inc. 3100 Central Expressway Santa Clara, California 95051

Tel.: (408) 720-2598 Fax: (408) 773-4029

Respectfully submitted,

Reg. No. 45,695 Attorney for Applicant(s)

-2-

Docket No. 2003-003R1 **PATENT**

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to:

Openinissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 11104

Annie Wong

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Carlson et al. Confirmation No. 2161

Serial No.: 10/790,956 Group Art Unit: 1639

Filed: March 1, 2004 Examiner: Unknown

For: **Evaluating Effects of Exposure**

Conditions on Drug Samples Over Time

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants submit herewith patents, publications and other information of which they are aware, which they believe an examiner may consider to be material to the patentability of the claims of this application, and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56.

While this Information Disclosure Statement may contain "material" information pursuant to 37 C.F.R. § 1.56, it is not intended to constitute an admission that any patent, publication or other information referred to herein is either "material" or "prior art" to the invention disclosed and claimed in the above-referenced application unless specifically designated as such. Applicants specifically reserve the right, where appropriate, to avoid or antedate any such reference by the appropriate arguments or showings under 37 C.F.R. § 1.131 and § 1.608, or any other appropriate means.

A completed PTO Form 1449 listing each reference is submitted herewith, and it is respectfully requested that an Examiner initialed copy of the PTO Form 1449 be returned to the undersigned. Copies of each reference listed on the PTO Form 1449 are enclosed except for copies of the U.S. patent documents which are not supplied in accordance with the OG notice of August 5, 2003, partially waiving the requirements of 37 C.F.R. §1.98(a)(2)(i).

Docket No. 2003-003R1 PATENT

This Information Disclosure Statement is being filed within three months of the filing or entry of the national stage of this application, or before the mailing of a first Office Action on the merits, whichever is later. No fee is required under 37 C.F.R. § 1.97(b). However, in the event that more than 90 days from filing have elapsed and a first Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge the fee required under 37 C.F.R. 1.17(p) to Deposit Account Number 50-0496.

The Examiner is hereby requested to consider these references and other information and make them of record in the above-referenced application. Applicants respectfully submit that the claims of this application are patentable over the above-cited references and information. Examination and allowance of this application at an early date are requested.

Respectfully submitted,

James H. Ackley, Registration No. 45,695

Date:

Symyx Technologies, Inc. 3100 Central Expressway Santa Clara, CA 95051

Tel: (408) 720-2598 Fax: (408) 773-4029

INFORMATION DISCLOSURE CITATION ATTORNEY'S DOCKET NO.: 2003-003R1 APPLICATION NO.: 10/790,956 APPLICATION APPLICATION NO.:			
Carlson et al.	ľ		
11ml 0 3 2004 H			
March 1, 2004 2161 1639	OUP: 9		
US PATENT DOCUMENTS			
	FILING DATE		
FOREIGN DOCUMENTS			
INITIALS PATENT NO. DATE COUNTRY CLASS CLASS Yes	ISLATION No		
WO 02/077614 10/3/2002 PCT G01N 13/00			
WO 03/014732 2/20/2003 PCT G01N 33/48			
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages Etc.)			
Abdel-Hamid., "Applications of Spectrometric Full Spectrum Quantitation (FSQ) Software for Multicomponent Analysis and Stability Studies of Pharmaceuticals", <i>Analytical Letters</i> , 33(13), 2000, pp. 2719-2735			
Dong et al., Study on the Fluorescence Characteristics of Alkaline Degradation of Cefadroxil, Cephradine, Cefotaximum Sodium and Amoxicillini", <i>Analytical Letters</i> , 31(6), 1998, pp. 1047-1			
Grant et al., "Influence of Water Activity in Organic Solvent + Water Mixtures on the Nature of the	he		
Crystallizing Drug Phase. 2. Ampicillin", <i>International Journal of Pharmaceutics</i> , 139, 1996, pp. 33-43 Schallreuter et al., Öxybenzone Oxidation Following Solar Irradiation of Skin: Photoprotection versus			
Antioxidant Inactivation", The Journal of Investigative Dermatology, 106(3), 1996, pp. 583-586			
EXAMINER: DATE CONSIDERED:			

Examiner: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.